CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. lowered its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 14.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,785 shares of the company’s stock after selling 1,951 shares during the period. E Fund Management Co. Ltd.’s holdings in CRISPR Therapeutics were worth $464,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics during the third quarter worth about $40,000. Darwin Wealth Management LLC acquired a new position in CRISPR Therapeutics during the 3rd quarter worth approximately $43,000. Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $39,000. Western Pacific Wealth Management LP lifted its holdings in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the period. Finally, Spire Wealth Management boosted its stake in shares of CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after buying an additional 1,482 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Up 5.1 %

CRISPR Therapeutics stock opened at $45.53 on Friday. The stock has a 50-day moving average price of $42.79 and a 200 day moving average price of $45.77. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $81.73. The stock has a market cap of $3.91 billion, a PE ratio of -10.42 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, Director John Greene acquired 7,000 shares of the firm’s stock in a transaction dated Wednesday, February 26th. The shares were acquired at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the acquisition, the director now directly owns 7,000 shares of the company’s stock, valued at $313,950. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have issued reports on CRSP. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. The Goldman Sachs Group cut their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday, February 13th. Royal Bank of Canada dropped their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a report on Wednesday, February 12th. Finally, Chardan Capital reduced their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and an average target price of $73.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.